In last trading session, Kronos Bio Inc (NASDAQ:KRON) saw 86209.0 shares changing hands with its beta currently measuring 1.89. Company’s recent per share price level of $1.14 trading at -$0.03 or -2.56% at ring of the bell on the day assigns it a market valuation of $68.50M. That closing price of KRON’s stock is at a discount of -100.88% from its 52-week high price of $2.29 and is indicating a premium of 39.47% from its 52-week low price of $0.69. Taking a look at company’s average trading volume volume of 516.05K if we extend that period to 3-months.
For Kronos Bio Inc (KRON), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 4 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.34 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Kronos Bio Inc (NASDAQ:KRON) trade information
Upright in the red during last session for losing -2.56%, in the last five days KRON remained trading in the green while hitting it’s week-highest on Friday, 06/28/24 when the stock touched $1.14 price level, adding 9.52% to its value on the day. Kronos Bio Inc’s shares saw a change of -8.80% in year-to-date performance and have moved 19.74% in past 5-day. Kronos Bio Inc (NASDAQ:KRON) showed a performance of 53.02% in past 30-days.
Wall Street analysts have assigned a consensus price target of 7.625 to the stock, which implies a rise of 85.05% to its current value. Analysts have been projecting 2.25 as a low price target for the stock while placing it at a high target of 13. It follows that stock’s current price would drop -97.37% in reaching the projected high whereas dropping to the targeted low would mean a loss of -97.37% for stock’s current value.
Kronos Bio Inc (KRON) estimates and forecasts
Statistics highlight that Kronos Bio Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -5.00% of value to its shares in past 6 months, showing an annual growth rate of 16.92% while that of industry is 15.40. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 21.50% from the last financial year’s standing.
3 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 1.7M for the same. And 3 analysts are in estimates of company making revenue of 1.63M in the next quarter. Company posted 1.86M and 917k of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -72.78% during past 5 years.
KRON Dividends
Kronos Bio Inc is more likely to be releasing its next quarterly report in August and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Kronos Bio Inc (NASDAQ:KRON)’s Major holders
Insiders are in possession of 25.17% of company’s total shares while institution are holding 36.24 percent of that, with stock having share float percentage of 48.43% . Investors also watch the number of corporate investors in a company very closely, which is 36.24% institutions for Kronos Bio Inc that are currently holding shares of the company. BVF Inc. is the top institutional holder at KRON for having 2.91 shares of worth $3.28 million. And as of Mar 31, 2024 , it was holding 4.83% of the company’s outstanding shares.
The second largest institutional holder is Vida Ventures Advisors, LLC , which was holding about 2.77 shares on Mar 31, 2024 . The number of shares represents firm’s hold over 4.60% of outstanding shares, having a total worth of $3.12 million.
On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Mar 31, 2024 , the former fund manager was holding 1.32 shares of worth $1.49 million or 2.19% of the total outstanding shares. The later fund manager was in possession of 559.54 shares on Mar 31, 2024 , making its stake of worth around $0.63 million in the company or a holder of 0.93% of company’s stock.
